{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:54:50Z","timestamp":1777611290173,"version":"3.51.4"},"reference-count":60,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.cmi.2016.08.029","type":"journal-article","created":{"date-parts":[[2016,9,12]],"date-time":"2016-09-12T23:15:28Z","timestamp":1473722128000},"page":"757-767","source":"Crossref","is-referenced-by-count":10,"title":["Pre-exposure prophylaxis: a useful tool to prevent human immunodeficiency virus infection?"],"prefix":"10.1016","volume":"22","author":[{"given":"G.","family":"Pialoux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Delaugerre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Cotte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Raffi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Cua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-M.","family":"Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2016.08.029_bib1","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1097\/QAD.0000000000000767","article-title":"Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM","volume":"29","author":"Phillips","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.cmi.2016.08.029_bib2","series-title":"Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV","author":"WHO","year":"2015"},{"key":"10.1016\/j.cmi.2016.08.029_bib3","doi-asserted-by":"crossref","first-page":"ofv126","DOI":"10.1093\/ofid\/ofv126","article-title":"Integrating antiretroviral strategies for human immunodeficiency virus prevention: post- and pre-exposure prophylaxis and early treatment","volume":"2","author":"Grant","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2016.08.029_bib4","doi-asserted-by":"crossref","DOI":"10.1177\/0956462416641813","article-title":"UK guideline for the use of HIV post-exposure prophylaxis following sexual exposure, 2015","author":"Cresswell","year":"2016","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.cmi.2016.08.029_bib5","doi-asserted-by":"crossref","first-page":"e0149892","DOI":"10.1371\/journal.pone.0149892","article-title":"Adolescent sexual and reproductive health services and implications for the provision of voluntary medical male circumcision: results of a systematic literature review","volume":"11","author":"Kaufman","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2016.08.029_bib6","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa1105243","article-title":"Prevention of HIV-1 infection with early antiretroviral therapy","volume":"365","author":"Cohen","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2016.08.029_bib7","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1126\/science.1193748","article-title":"Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women","volume":"329","author":"Abdool Karim","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.cmi.2016.08.029_bib8","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"Baeten","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2016.08.029_bib9","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMoa1110711","article-title":"Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana","volume":"367","author":"Thigpen","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2016.08.029_bib10","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"Grant","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2016.08.029_bib11","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1202614","article-title":"Preexposure prophylaxis for HIV infection among African women","volume":"367","author":"Van Damme","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2016.08.029_bib12","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1177\/154510970300200302","article-title":"Pre-exposure chemoprophylaxis as an HIV prevention strategy","volume":"2","author":"Youle","year":"2003","journal-title":"J\u00a0Int Assoc Physicians AIDS Care"},{"key":"10.1016\/j.cmi.2016.08.029_bib13","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/1741-7015-11-186","article-title":"Challenges and opportunities for oral pre-exposure prophylaxis in the prevention of HIV infection: where are we in Europe?","volume":"11","author":"Molina","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.cmi.2016.08.029_bib14","first-page":"1073","article-title":"Pre-exposure prophylaxis of HIV infection","volume":"64","author":"Gatey","year":"2014","journal-title":"Rev Prat"},{"key":"10.1016\/j.cmi.2016.08.029_bib15","doi-asserted-by":"crossref","first-page":"20309","DOI":"10.7448\/IAS.19.1.20309","article-title":"A\u00a0systematic review of interventions to improve prevention of mother-to-child HIV transmission service delivery and promote retention","volume":"19","author":"Ambia","year":"2016","journal-title":"J\u00a0Int AIDS Soc"},{"key":"10.1016\/j.cmi.2016.08.029_bib16","doi-asserted-by":"crossref","first-page":"14ra4","DOI":"10.1126\/scitranslmed.3000391","article-title":"Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection","volume":"2","author":"Garc\u00eda-Lerma","year":"2010","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.cmi.2016.08.029_bib17","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1371\/journal.pmed.0050028","article-title":"Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir","volume":"5","author":"Garc\u00eda-Lerma","year":"2008","journal-title":"PLoS Med"},{"issue":"12","key":"10.1016\/j.cmi.2016.08.029_bib18","doi-asserted-by":"crossref","first-page":"e50632","DOI":"10.1371\/journal.pone.0050632","article-title":"Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen","volume":"7","author":"Radzio","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2016.08.029_bib19","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/QAI.0b013e3182234a51","article-title":"Delayed maturation of antibody avidity but not seroconversion in rhesus macaques infected with simian HIV during oral pre-exposure prophylaxis","volume":"57","author":"Curtis","year":"2011","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"5239","key":"10.1016\/j.cmi.2016.08.029_bib20","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1126\/science.270.5239.1197","article-title":"Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine","volume":"270","author":"CC1","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.cmi.2016.08.029_bib21","doi-asserted-by":"crossref","first-page":"e74404","DOI":"10.1371\/journal.pone.0074404","article-title":"Multicompartmental pharmacokinetic model of tenofovir delivery by a vaginal gel","volume":"8","author":"Gao","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2016.08.029_bib22","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1093\/jac\/dku162","article-title":"Tenofovir diphosphate concentrations and prophylactic effect in a macaque model\u00a0of rectal simian HIV transmission","volume":"69","author":"Anderson","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2016.08.029_bib23","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1517\/17425255.2015.1027682","article-title":"Pharmacokinetics of antiretrovirals in mucosal tissues","volume":"11","author":"Cottrell","year":"2015","journal-title":"Exp Opin Drug Metab Toxicol"},{"key":"10.1016\/j.cmi.2016.08.029_bib24","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","article-title":"On-demand preexposure prophylaxis in men at high risk for HIV-1 infection","volume":"373","author":"Molina","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"10013","key":"10.1016\/j.cmi.2016.08.029_bib25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","article-title":"Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial","volume":"387","author":"McCormack","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2016.08.029_bib26","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1473-3099(14)70937-5","article-title":"Single-agent tenofovir versus combination emtricinatine plus tenofovir for preexposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial","volume":"14","author":"Baeten","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2016.08.029_bib27","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/infdis\/jiw077","article-title":"A\u00a0Translational pharmacology approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without emtricitabine","volume":"214","author":"Cottrell","year":"2016","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2016.08.029_bib28","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/COH.0000000000000219","article-title":"The promise and pitfalls of long-acting injectable agents for HIV prevention","volume":"11","author":"Landovitz","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.cmi.2016.08.029_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2016.01.017","article-title":"Nanomedicine in the development of anti-HIV microbicides","author":"Das Neves","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.cmi.2016.08.029_bib30","article-title":"The preexposure prophylaxis for HIV prevention","author":"Delaugerre","year":"2016","journal-title":"Virologie"},{"key":"10.1016\/j.cmi.2016.08.029_bib31","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/QAD.0000000000000556","article-title":"Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women","volume":"29","author":"Grant","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.cmi.2016.08.029_bib32","first-page":"187","article-title":"Minority HIV-1 drug-resistant mutations and prevention of mother-to-child transmission: perspectives for resource-limited countries","volume":"16","author":"Samuel","year":"2014","journal-title":"AIDS Rev"},{"key":"10.1016\/j.cmi.2016.08.029_bib33","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/infdis\/jiv110","article-title":"Antibody maturation in women who acquire HIV infection while using antiretroviral preexposure prophylaxis","volume":"212","author":"Laeyendecker","year":"2015","journal-title":"J\u00a0Infect Dis"},{"issue":"3","key":"10.1016\/j.cmi.2016.08.029_bib34","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/infdis\/jit189","article-title":"Prophylactic efficacy of oral emtricitabine and tenofovir disoproxil fumarate combination therapy against a tenofovir-resistant simian\/human immunodeficiency virus containing the K65R mutation in macaques","volume":"208","author":"Cong","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2016.08.029_bib35","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1093\/infdis\/jiu026","article-title":"Sensitive tenofovir resistance screening of HIV-1 from the genital and blood compartments of women with breakthrough infections in the CAPRISA 004 Tenofovir Gel Trial","volume":"209","author":"Wei","year":"2014","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2016.08.029_bib36","first-page":"1211","article-title":"Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis","volume":"211","author":"Lehman","year":"2015","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2016.08.029_bib37","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1093\/infdis\/jiu233","article-title":"HIV-1 drug resistance in the iPrEx Preexposure Prophylaxis Trial","volume":"210","author":"Liegler","year":"2014","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2016.08.029_bib38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/QAD.0000000000000915","article-title":"Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation","volume":"30","author":"Weis","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.cmi.2016.08.029_bib39","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.2217\/fmb.15.106","article-title":"Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection","volume":"10","author":"Sluis-Cremer","year":"2015","journal-title":"Future Microbiol"},{"key":"10.1016\/j.cmi.2016.08.029_bib40","unstructured":"Knox DC, Tan DH, Harrigan PR, Anderson PL. HIV-1 infection with multiclass resistance despite preexposure prophylaxis (PrEP). CROI 2016 February 22\u201325, 2016. Boston, MA (Abstract Number 169aLB)."},{"key":"10.1016\/j.cmi.2016.08.029_bib41","first-page":"125","article-title":"Pre-exposure prophylaxis for sexually-acquired HIV risk management: a review","volume":"7","author":"Wilton","year":"2015","journal-title":"HIV AIDS"},{"key":"10.1016\/j.cmi.2016.08.029_bib42","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/QAI.0000000000000351","article-title":"Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study","volume":"67","author":"Liu","year":"2014","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cmi.2016.08.029_bib43","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1093\/infdis\/jiv239","volume":"212","author":"Gandhi","year":"2015","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2016.08.029_bib44","doi-asserted-by":"crossref","first-page":"18899","DOI":"10.7448\/IAS.17.1.18899","article-title":"IV pre-exposure prophylaxis for people who inject drugs: a review of current results and an agenda for future research","volume":"17","author":"Escudero","year":"2014","journal-title":"J\u00a0Int AIDS Soc"},{"key":"10.1016\/j.cmi.2016.08.029_bib45","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/QAD.0000000000000613","article-title":"The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugs","volume":"29","author":"Martin","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.cmi.2016.08.029_bib46","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1402269","article-title":"Tenofovir-based preexposure prophylaxis for HIV infection among African women","volume":"372","author":"Marrazzo","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2016.08.029_bib47","series-title":"FACTS 001 phase III trial of pericoital tenofovir 1% gel for HIV prevention in women","author":"Rees","year":"2015"},{"key":"10.1016\/j.cmi.2016.08.029_bib48","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1506110","article-title":"Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. MTN-020\u2013ASPIRE Study Team","author":"Baeten","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2016.08.029_bib49","unstructured":"Ne Al, Kapiga S, Bekker LG, Devlin B, Borremans M, Rosenberg Z, IPM 027\/The Ring Study Research Center Teams. Safety and efficacy of dapivirine vaginal ring for HIV-1 prevention in African Women CROI 2016 February 22\u201325, 2016; Boston, MA; Abstract Number: 110LB."},{"issue":"22","key":"10.1016\/j.cmi.2016.08.029_bib50","doi-asserted-by":"crossref","DOI":"10.2807\/ese.13.22.18888-en","article-title":"Prevalence of hepatitis C and hepatitis B infection in the HIV-infected population of France, 2004","volume":"13","author":"Larsen","year":"2008","journal-title":"Euro Surveill"},{"key":"10.1016\/j.cmi.2016.08.029_bib51","doi-asserted-by":"crossref","first-page":"19640","DOI":"10.7448\/IAS.17.4.19640","article-title":"Incidence of recent HCV infection among persons seeking voluntary counselling and testing for HIV and sexually transmitted infections in Taiwan","volume":"17","author":"Su","year":"2014","journal-title":"J\u00a0Int AIDS Soc"},{"key":"10.1016\/j.cmi.2016.08.029_bib52","doi-asserted-by":"crossref","first-page":"ofv115","DOI":"10.1093\/ofid\/ofv115","article-title":"Risk factors for sexual transmission of hepatitis C virus among human immunodeficiency virus-infected men who have sex with men: a case\u2013control study","volume":"2","author":"Vanhommerig","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2016.08.029_bib53","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/cid\/cis694","article-title":"Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic","volume":"55","author":"Wandeler","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2016.08.029_bib54","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1093\/cid\/cit054","article-title":"Prevalent and incident hepatitis C virus infection among HIV-infected men who have sex with men engaged in primary care in a Boston community health center","volume":"56","author":"Garg","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2016.08.029_bib55","first-page":"213","article-title":"Incidence and risk factors for incident Hepatitis C infection among men who have sex with men with HIV-1 infection in a large Urban HIV clinic in Tokyo","volume":"65","author":"Nishijima","year":"2014","journal-title":"J\u00a0AIDS"},{"key":"10.1016\/j.cmi.2016.08.029_bib56","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/jvh.12366","article-title":"Acute hepatitis C infection in HIV-negative men who have sex with men","volume":"22","author":"McFaul","year":"2015","journal-title":"J\u00a0Viral Hepatol"},{"key":"10.1016\/j.cmi.2016.08.029_bib57","doi-asserted-by":"crossref","first-page":"541","DOI":"10.7326\/0003-4819-156-8-201204170-00001","article-title":"The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men","volume":"156","author":"Juusola","year":"2012","journal-title":"Ann Intern Med"},{"issue":"4 Suppl.\u00a03","key":"10.1016\/j.cmi.2016.08.029_bib58","article-title":"PrEP implementation: moving from trials to policy and practice","volume":"18","author":"C\u00e1ceres","year":"2015","journal-title":"J\u00a0Int AIDS Soc"},{"key":"10.1016\/j.cmi.2016.08.029_bib59","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1016\/S2352-3018(15)00056-9","article-title":"Effect of pre-exposure prophylaxis and combination HIV prevention for men who have sex with men in the UK: a mathematical modelling study","volume":"3","author":"Punyacharoensin","year":"2016","journal-title":"Lancet HIV"},{"key":"10.1016\/j.cmi.2016.08.029_bib60","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1016\/S2352-3018(15)00060-0","article-title":"HIV transmission in MSM: considerations for PrEP scale-up","volume":"3","author":"Arnold","year":"2016","journal-title":"Lancet HIV"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X16303780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X16303780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T05:47:44Z","timestamp":1657259264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X16303780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":60,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S1198743X16303780"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2016.08.029","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]}}}